| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Pre-clinical data readout example | Lead DOR inhibitor ADC Solid tumors | Pre-clinical | — | Antibody-Drug Conjugates (ADCs) | Oncology | ||
Pre-clinical data readout example | Lead DOR inhibitor ADC Solid tumors | Pre-clinical | — | Antibody-Drug Conjugates (ADCs) | Oncology | ||
Pre-clinical data readout example | Lead DOR inhibitor ADC Solid tumors | Pre-clinical | — | Antibody-Drug Conjugates (ADCs) | Oncology |
Recent Updates
Recently added Catalysts
TuHURA Biosciences, Inc.$2.16
-0.36 (-13.92%)
D 39Pipeline Score Overvalued Biotech · Clinical
Market Cap
159.21 M
EPS
-0.60
P/E Ratio
-
Value Trade
1.03 M
SEC Financials
Q1 2026Dilution Risk
Revenue
-
R&D Expenses
5.23 M
Operating CF
-4.41 M
Total Assets
29.70 M
Total Liabilities
6.51 M
Equity
23.19 M
D/E Ratio
12,345
2.88 %
Week
-10.07 %
1 Month
113.68 %
3 Month
56.25 %
6 Month
-99.9 %
5 Year
-100 %
All Time
Cash Data
Cash Position
6.30 M
Monthly Burn
1.47 M
Runway
2.9 mo
Burn Trend
SEC Filing
May 15, 2026
Overview
Volume
4.51 M
52 Week Range
0.41 - 3.90
% held by Insiders
34.65 %
% held by Institutions
14.81 %
Enterprise Value
153.64 M
Total Shares
63.75 M
Short %
31.96 %
Float Shares
24.29 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D39
Pipeline Score $53M
Pipeline ValueOvervalued
Valuation Signal4
Drugs Scored0.3x
rNPV / MCap Top 57%
Micro Cap (rank 390 of 905)
Percentile RankTuHURA Biosciences, Inc. faces pipeline headwinds (39/100), with $1.5B risk-adjusted pipeline value, led by dalazatide in Plaque Psoriasis (Phase 1), across $56B in total addressable markets, but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| dalazatide Small molecule | Plaque Psoriasis | Phase 1 | NCT02435342 | 20% | $1.0B | COMPLETED | 24 | - | - | Mar 1, 2015 | - | May 6, 2015 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
IFx-2.0 | advanced or metastatic Merkel cell carcinoma | Phase 3 | 2025-06-24 | |||
IFx-2.0 | advanced or metastatic Merkel cell carcinoma | Phase 3 | 2025-06-24 | |||
IFx-2.0 | advanced or metastatic Merkel cell carcinoma | Phase 3 | 2025-06-24 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in HURA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
HURA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
HURA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
HURA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
HURA Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
HURA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
HURATuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers
TuHURA Biosciences has filed an IND application with the FDA for TBS-2025, a VISTA-inhibiting antibody aimed at treating molecularly defined subsets of Acute Myeloid Leukemia (AML) and other blood cancers. The FDA has provided guidance on the development plan, allowing TuHURA to combine Phase 1b and Phase 2 studies for efficiency. The company aims to initiate the trial in late 2026, addressing significant unmet medical needs in AML and high-risk myelodysplasia patients.
Read more →HURATuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update
TuHURA Biosciences reported its Q1 2026 financial results, highlighting a $50 million credit facility to support operations. The company anticipates key milestones, including FDA discussions for its VISTA inhibitor and the initiation of a Phase 1b/2 trial for TBS-2025. Additionally, TuHURA received FDA Orphan Drug Designation for IFx-2.0 in melanoma.
Read more →HURATuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference
TuHURA Biosciences, Inc. will present at the 4th Annual H.C. Wainwright BioConnect Investor Conference on May 19, 2026. CEO James A. Bianco will participate in a fireside chat, discussing the company's Phase 3 immuno-oncology developments. TuHURA is focused on overcoming resistance to cancer therapies with its lead product, IFx-2.0, and other innovative candidates.
Read more →HURAUNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Unless the context indicates otherwise in this Unaudited Pro Forma Condensed Combined Financial Information, references to "TuHURA," "TuHURA Biosciences, Inc."
TuHURA Biosciences, Inc. has successfully completed its merger with Kineta, enhancing its capabilities and expanding its portfolio. The mergers were treated as a business combination under U.S. GAAP, with TuHURA identified as the accounting acquirer. Following the merger, TuHURA plans to advance the clinical development of Kineta's trials and explore synergies with its ongoing studies. The financial information presented reflects the combined operations and anticipated future developments post-merger.
Read more →HURATuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028
TuHURA Biosciences has announced a $50 million credit facility to fund its clinical pipeline, including the Phase 3 trial of IFx-2.0. The agreement allows the company to draw funds as needed, with a 12% interest rate and a five-year maturity. This funding is expected to support operations through key milestones, including anticipated Phase 3 results. The company also granted a royalty on sales of products based on IFx-2.0 to the lender.
Read more →HURATuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operations
TuHURA Biosciences has appointed Amanda Garofalo as Senior Vice President of Clinical Operations. With over 20 years of experience in drug development, she will oversee daily clinical operations and collaborate with the executive team. Her expertise is anticipated to strengthen TuHURA's clinical programs, including the Phase 3 trial of IFx-2.0.
Read more →HURATuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
TuHURA Biosciences reported its financial results for Q4 and the full year of 2025, highlighting strong progress in its clinical development pipeline. The company has initiated a Phase 3 trial for its lead candidate, IFx-2.0, and made advancements in its VISTA inhibiting antibody program. Financially, TuHURA raised $21.2 million but also faced increased operating expenses.
Read more →HURACraig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers
TuHURA Biosciences has appointed Dr. Craig Tendler as the leader of its VISTA program targeting acute myeloid leukemia (AML) and other blood cancers. Dr. Tendler, with over 29 years of experience in oncology, will oversee clinical development strategies for the company's TBS-2025 antibody. His previous successes in drug approvals are expected to enhance TuHURA's regulatory pathways.
Read more →HURATuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement
TuHURA Biosciences has confirmed compliance with Nasdaq's minimum bid price requirement, with its stock closing above $1.00 for 11 consecutive business days. The company is focused on advancing its clinical trials, including a Phase 3 trial for IFX-2.0 in Merkel Cell Carcinoma and preparing for a Phase 2 study of TBS-2025 in relapsed/refractory AML.
Read more →HURATuHURA Biosciences Announces Participation in Upcoming Investor Conferences
TuHURA Biosciences, Inc. announced its participation in two upcoming investor conferences, the Citizens Life Science Conference and the Leerink Global Healthcare Conference. Dr. James Bianco, the CEO, will represent the company at these events. TuHURA is focused on developing innovative therapies to combat resistance to cancer immunotherapy, particularly through its lead product, IFx-2.0.
Read more →HURATuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers
TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers
Read more →HURATuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
TuHURA Biosciences, Inc. will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026. The company focuses on developing novel immuno-oncology therapeutics to combat resistance to cancer treatments. Their lead product, IFx-2.0, is currently in a Phase 3 trial for advanced Merkel Cell Carcinoma. Additionally, TuHURA has expanded its pipeline through a merger with Kineta Inc.
Read more →HURATuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma
TuHURA Biosciences has received FDA Orphan Drug Designation for its drug IFx-2.0, aimed at treating stage IIB to IV cutaneous melanoma. This designation is based on positive results from a Phase 1 study, which indicated safety and potential benefits for patients resistant to existing therapies. The company is now focusing on completing enrollment for a Phase 3 study combining IFx-2.0 with Keytruda for advanced Merkel Cell Carcinoma.
Read more →HURATuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone
TuHURA Biosciences announced that Kintara's REM-001 clinical trial met its primary safety endpoint, showing signs of clinical efficacy in patients with metastatic cutaneous breast cancer. This achievement triggers the release of 1,539,958 shares of TuHURA common stock to legacy Kintara stockholders, expected within ten business days. TuHURA continues to develop novel immuno-oncology therapies.
Read more →HURATuHURA Biosciences Provides Corporate Update Following Recent Financing
TuHURA Biosciences provided a corporate update following a $15.6 million financing. The company is advancing its Phase 3 trial of IFx-2.0 for Merkel cell carcinoma and received positive feedback on its VISTA inhibiting antibody, TBS-2025, during a recent symposium. The company anticipates significant milestones in 2026, including trial enrollment completion and data presentations.
Read more →HURATuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering
TuHURA Biosciences, Inc. has announced a $15.6 million registered direct offering to raise funds for its operations and development of cancer therapies. The offering includes shares and warrants with expected closings in three tranches. The proceeds will be used for working capital and to address a bridge note obligation. TuHURA is focused on overcoming resistance to cancer immunotherapy.
Read more →HURATuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and Exposition
TuHURA Biosciences presented new findings at the ASH Annual Meeting, highlighting the Delta Opioid Receptor (DOR) as a potential target for overcoming resistance to immune checkpoint inhibitors. The research demonstrated that DOR inhibition can reduce the immunosuppressive capabilities of Myeloid-Derived Suppressor Cells (MDSCs) and tumor-associated macrophages (TAMs). This suggests that targeting DOR could enhance the effectiveness of cancer immunotherapies.
Read more →HURATuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
TuHURA Biosciences, Inc. reported its third quarter 2025 financial results and provided updates on its clinical trials. The Phase 3 trial for IFx-2.0 as an adjunctive therapy to Keytruda for advanced Merkel cell carcinoma is currently underway. The company is also preparing to submit a Phase 2 study plan for TBS-2025 in AML. Additionally, TuHURA's DOR technology has been selected for presentation at the upcoming ASH Annual Meeting.
Read more →HURATuHURA Biosciences Discovery Research on Targeting the Delta Opioid Receptor (DOR) to Reprogram Myeloid-Derived Suppressor Cells (MDSCs) Selected for Oral Presentation at the 67th ASH Annual Meeting and Exposition
TuHURA Biosciences has announced that its research on the Delta Opioid Receptor (DOR) targeting Myeloid-Derived Suppressor Cells (MDSCs) has been selected for an oral presentation at the 67th ASH Annual Meeting. This research demonstrates the expression of DOR on MDSCs and tumor-associated macrophages, indicating a novel target for overcoming resistance to cancer immunotherapy. The findings suggest that DOR inhibition could effectively reprogram immunosuppressive mechanisms in the tumor microenvironment.
Read more →HURABusiness Except as otherwise specified or indicated by the context, references to "we," "us," "our" or the "company" are to TuHURA Biosciences, Inc. and its wholly owned subsidiaries. Overview We are a clinical stage imm
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, aims to develop innovative therapeutics to address cancer immunotherapy resistance. The company is advancing its lead product candidate, IFx-2.0, in a Phase 3 trial as an adjunctive therapy to Keytruda for treating advanced Merkel cell carcinoma. Additionally, TuHURA has acquired TBS-2025, a monoclonal antibody targeting VISTA to investigate its synergy with menin inhibitors for acute myeloid leukemia. Both initiatives reflect TuHURA's commitment to expanding its therapeutic offerings in oncology.
Read more →HURATuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference
TuHURA Biosciences, Inc. will present at the 27th Annual H.C. Wainwright Global Investment Conference from September 8-10, 2025, in New York City. CEO James Bianco will provide an overview of the company's Phase 3 immune-oncology developments. The presentation will be available for replay on the company's website. TuHURA focuses on overcoming resistance to cancer immunotherapy.
Read more →HURATuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update Completed the acquisition of Kineta, Inc. and its VISTA inhibiting monoclonal antibody (mAb), now named “TBS-2
TuHURA Biosciences, Inc. has reported its financial results for the second quarter of 2025 and announced several corporate updates. The company completed its acquisition of Kineta, Inc., including the VISTA inhibiting monoclonal antibody TBS-2025, and plans to start a Phase 2 trial for this treatment in NPM1-mutated AML. Additionally, TuHURA launched a Phase 3 trial for IFx-2.0, an adjunctive therapy with Pembrolizumab for Merkel Cell Carcinoma, under special FDA protocol. The company secured $12.5 million in financing and gained entry into the Russell indexes.
Read more →HURATuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
TuHURA Biosciences, Inc. has been added to the Russell 3000® and Russell 2000® indexes, effective June 27, 2025. This milestone highlights the company's growth since going public. TuHURA is currently enrolling patients in a Phase 3 trial for IFx-2.0 as a treatment for advanced Merkel cell carcinoma and plans to advance a novel anti-VISTA antibody into a Phase 2 trial for Acute Myeloid Leukemia.
Read more →HURATuHURA Biosciences Completes Acquisition of Kineta
TuHURA Biosciences has successfully completed the acquisition of Kineta, adding the VISTA inhibiting monoclonal antibody TBS-2025 to its pipeline. This acquisition is expected to enhance TuHURA's immuno-oncology offerings and is set to initiate a Phase 2 trial in late 2025. The acquisition also triggers additional funding from a previous financing round.
Read more →HURATuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell Carcinoma
TuHURA Biosciences has initiated a Phase 3 accelerated approval trial for IFx-2.0, an adjunctive therapy to Keytruda for advanced Merkel cell carcinoma. The trial, conducted under a Special Protocol Assessment with the FDA, aims to evaluate the drug's effectiveness and safety. The primary endpoint is the Overall Response Rate, with secondary endpoints including Progression Free Survival. This trial unlocks additional funding for the company.
Read more →HURATuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals TAMPA, Fla., and Seattle, Wash.
TuHURA Biosciences, Inc. and Kineta, Inc. recently announced that their respective stockholders approved the proposed merger and related proposals during special meetings held on June 23, 2025. This merger aims to combine TuHURA's developed immune-oncology technologies with Kineta's expertise in immunotherapies to enhance their impact in cancer treatment. Following the approvals, the companies anticipate closing the merger quickly, pending the fulfillment of remaining closing conditions. TuHURA is also set to initiate a Phase 3 trial for its lead product, IFx-2.0, soon.
Read more →HURAFDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for IFx-2.0 in Advanced or Metastatic Merkel Cell Carcinoma
FDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for IFx-2.0 in Advanced or Metastatic Merkel Cell Carcinoma
Read more →HURATuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance
TuHURA Biosciences, Inc. has successfully entered into a private equity financing transaction, securing $12.5 million for its pipeline aimed at overcoming primary resistance to cancer immunotherapy. The funding consists of commitments for the issuance of shares alongside warrants. Additionally, the company has received $3.0 million from the cash exercise of warrants. The proceeds are expected to support the company's upcoming Phase 3 trial and a proposed merger with Kineta, Inc.
Read more →HURATuHURA Biosciences Presents IFx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of Clinical Oncology Annual Meeting
TuHURA Biosciences Presents IFx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of Clinical Oncology Annual Meeting
Read more →HURATuHURA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update Anticipates initiating the Company's Phase 3 accelerated approval trial of IFx-Hu2.0 as adjunctive therapy with Keytru
TuHURA Biosciences, Inc. reported its first quarter 2025 financial results and provided a corporate update. The company anticipates starting a Phase 3 trial for its drug IFx-Hu2.0 in treating advanced Merkel cell carcinoma by Q2 2025, backed by an agreement with the FDA. Additionally, they have initiated a Phase 1b/2a trial for the same drug in previously untreated Merkel cell carcinoma of unknown primary origin. TuHURA aims to close its acquisition of Kineta, enhancing its pipeline, while experiencing rising research and administrative costs this quarter.
Read more →HURATuHURA Biosciences, Inc. to Present at the 3rd Annual H.C. Wainwright BioConnect Conference
TuHURA Biosciences, Inc. to Present at the 3rd Annual H.C. Wainwright BioConnect Conference
Read more →HURATuHURA Biosciences, Inc. Initiates Phase 1b/2a Study of IFx-Hu2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Metastatic Merkel Cell Carcinoma of Unknown Primary Origin (MCCUP)
TuHURA Biosciences, Inc. Initiates Phase 1b/2a Study of IFx-Hu2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Metastatic Merkel Cell Carcinoma of Unknown Primary Origin (MCCUP)
Read more →HURATuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Research Annual Meeting
TuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Research Annual Meeting
Read more →HURATuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting
TuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting
Read more →HURATuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management
TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management
Read more →HURATuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update Phase 3 IFx-2.0 accelerated approval trial as adjunctive therapy with Keytruda (pembrolizumab) in 1 st line therapy fo
TuHURA Biosciences, Inc. recently announced its financial results for fiscal year 2024 and provided an update on its Phase 3 clinical trial for IFx-2.0 in conjunction with Keytruda for advanced Merkel cell carcinoma. The company anticipates initiating patient enrollment in Q2 2025 and conducting the trial under a Special Protocol Assessment agreement with the FDA. Additionally, TuHURA is preparing to acquire Kineta and advance its VISTA inhibiting antibody within its product pipeline. The transformation year saw TuHURA successfully list on NASDAQ and secure necessary capital for future developments.
Read more →HURAOvercoming Resistance to Cancer Immunotherapy Presentation | March 2025 tuhurabio.com Filed by TuHURA Biosciences, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under
TuHURA Biosciences, Inc. has provided an update on its cancer immunotherapy initiatives, highlighting advancements in its pipeline and regulatory engagement. Key developments include the successful trial outcomes for its IFx-2.0 candidate and a potential merger with Kineta, which could enhance its development capabilities. However, the company faces a partial clinical hold on its trial initiation due to CMC requirements, posing risks to its projected timelines. The upcoming period will be critical as the firm anticipates several key data readouts and regulatory milestones.
Read more →HURATuHURA Biosciences, Inc Appoints Craig L. Tendler M.D., Former Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs, Johnson & Johnson Innovative Medicine Research & Development, to its
TuHURA Biosciences, Inc. has appointed Dr. Craig L. Tendler, previously with Johnson & Johnson, to its Board of Directors. Dr. Tendler brings extensive experience overseeing major oncology drug approvals and FDA breakthrough designations. His expertise is expected to bolster TuHURA's development programs, particularly in advancing its lead candidate IFx-2.0 through Phase 3 trials set to initiate in Q2 2025. The company is also progressing with plans for its VISTA inhibiting antibody following a merger with Kineta.
Read more →HURATuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference
TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference
Read more →HURATuHURA Biosciences, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
TuHURA Biosciences, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
Read more →HURATuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc. Opportunistic acquisition adds Phase 2 novel checkpoint inhibitor (KVA12123) to TuHURA s late stage pipeline Targeting Phase 2a/b t
TuHURA Biosciences, Inc. has announced a definitive merger agreement to acquire Kineta, Inc., which will bring the novel checkpoint inhibitor KVA12123 to TuHURA's development pipeline. This acquisition is seen as a strategic move to enhance TuHURA's capabilities in addressing cancer immunotherapy resistance. The transaction, expected to close in Q1 2025, includes a combination of cash and shares for Kineta's stockholders. Regulatory and stockholder approvals will be required before the merger can be finalized.
Read more →HURATuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Busines
TuHURA Biosciences, Inc. has outlined its development pathway for a Phase 3 accelerated approval trial of IFx-2.0 in treating advanced or metastatic Merkel Cell Carcinoma. The company has also entered a non-binding agreement to acquire KVA12123, a novel antibody that could strengthen its pipeline. Additionally, TuHURA announced key leadership appointments to facilitate operational execution. The firm is targeting significant milestones for the remainder of 2024 and into 2025, potentially enhancing its position in the cancer immunotherapy landscape.
Read more →HURATuHURA Biosciences (Nasdaq: HURA) Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC
TuHURA Biosciences (Nasdaq: HURA) Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC
Read more →HURATuHURA Biosciences (NASDAQ:HURA) to Present at the Virtual Investor "New to the Street" Event
TuHURA Biosciences (NASDAQ:HURA) to Present at the Virtual Investor "New to the Street" Event
Read more →HURATuHURA Biosciences Completes Merger Transaction with Kintara Therapeutics • Combined company will operate as TuHURA Biosciences, Inc. and advance pipeline of novel technologies to overcome resistance to cancer imm
TuHURA Biosciences has successfully completed its merger with Kintara Therapeutics, now operating under the TuHURA name. The combined entity will focus on advancing innovative technologies aimed at overcoming resistance to cancer immunotherapy. A significant highlight is the planned initiation of a Phase 3 accelerated approval trial for IFx-2.0, targeting Merkel Cell carcinoma in the first half of 2025. The merger is projected to enhance TuHURA's capital position, having secured $31 million in funding to support its operations through late 2025.
Read more →HURAKintara Therapeutics Announces Correction to Prior Announcement Regarding CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on
Kintara Therapeutics has issued a correction to a prior announcement regarding the issuance of Contingent Value Rights (CVRs) in connection with its proposed merger with TuHURA Biosciences. The company clarified that CVRs will be issued to stockholders immediately before a planned reverse stock split, rather than based on an earlier stated record date. The merger is expected to close on October 18, 2024, subject to regulatory approval. Kintara reassured stakeholders that this correction will not affect eligible stockholders.
Read more →HURAKintara Therapeutics Announces Record Date for CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on
Kintara Therapeutics has announced a record date of October 17, 2024, for the issuance of Contingent Value Rights to its stockholders in connection with its merger with TuHURA Biosciences. The merger is expected to close on October 18, 2024, pending regulatory approvals. The stockholders have already approved a reverse stock split which is likely to occur before the merger is finalized. The merger aims to enhance Kintara's capabilities in developing cancer therapies.
Read more →HURATUHURA BIOSCIENCES, INC. AND SUBSIDIARY CONDENSED CONSOLIDATED FINANCIAL STATEMENTS As of
TuHURA Biosciences, Inc. has released its condensed consolidated financial statements for the six months ended June 30, 2024. The company reported a net loss of $10,107,377, an increase from the $22,093,733 loss in the same period last year, suggesting ongoing financial challenges. Despite a significant rise in cash and cash equivalents, the total liabilities increased to $21,052,032, raising concerns about the company's financial stability. The company continues to advance its cancer vaccine development programs and expects to start a Phase II trial for Merkel cell carcinoma in the latter half of 2024.
Read more →HURAKintara Therapeutics Announces Fiscal 2024 Financial Results and Provides Corporate Update
Kintara Therapeutics recently announced its financial results for fiscal Q4 2024 and provided a corporate update. The company is moving forward with a merger with TuHURA Biosciences, following stockholder approval. Financially, Kintara showed a reduced net loss compared to the previous year, aided by decreased research expenses, though it reported only $4.9 million in cash. Additionally, Kintara's REM-001 study has commenced, supported by a grant from the NIH to advance its cancer treatment options.
Read more →HURAIt is imperative for ALL stockholders to VOTE your shares. Voting deadline is October 3 rd at 11:59 p.m., EST Kintara Therapeutics, Inc. (“Kintara”) has adjourned their Special Meeting of Stockholders until
Kintara Therapeutics has announced that its Special Meeting of Stockholders has been adjourned to October 4, 2024, due to not reaching the necessary voting threshold for key proposals related to its merger with TuHURA Biosciences. The company is urging all eligible stockholders to vote by the October 3 deadline to support the merger, which is crucial for the future of Kintara. Prominent advisory firms have recommended voting in favor of the proposals, highlighting optimism about the merger's potential benefits.
Read more →HURAKintara Therapeutics Announces Adjournment of Special Meeting of Stockholders until
Kintara Therapeutics has announced the adjournment of its Special Meeting of Stockholders until October 4, 2024, due to insufficient votes on key proposals. The proposals include increasing the number of authorized shares and reincorporating the company from Nevada to Delaware, both essential steps concerning a proposed merger with TuHURA Biosciences. The adjournment allows stockholders more time to consider the implications but reflects challenges in securing necessary support, as highlighted by the unmet voting threshold.
Read more →HURAKintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA Biosciences • Stockholders must vote by 11:59 p.m. ET on
Kintara Therapeutics is reminding its stockholders to vote by September 19, 2024, to approve the proposed merger with TuHURA Biosciences. Approval is needed for Proposals 3 & 5, which entail increasing authorized shares and reincorporating from Nevada to Delaware. Prominent advisory services have recommended a vote in favor of these proposals. If shareholder approval is not achieved, the merger cannot proceed, putting the future of Kintara at risk.
Read more →HURAKintara Therapeutics Provides Update on Corporate Developments and REM-001 Clinical Study
Kintara Therapeutics provided an update on their corporate developments including a merger with TuHURA Biosciences and progress on the REM-001 clinical study. The REM-001 study, which targets cutaneous metastatic breast cancer, has currently enrolled four out of the intended ten patients. The completion of this merger is crucial for Kintara's financial sustainability, as failure to proceed could lead to significant operational challenges. A special stockholder meeting is scheduled for September 20, 2024, to discuss the merger and related proposals.
Read more →HURAKintara Therapeutics to Hold Special Meeting of Stockholders to Allow for Completion of the Proposed Merger with TuHURA Biosciences, Inc. • Stockholders must vote by 11:59 p.m., Eastern Time, on
Kintara Therapeutics is set to hold a Special Meeting of Stockholders on September 20, 2024, to vote on the proposed all-stock merger with TuHURA Biosciences, Inc. Stockholders must cast their votes by September 19, 2024, for them to be counted. The merger aims to combine resources and expertise to advance new oncology therapies. If approved, Kintara equityholders will own approximately 2.85% of the new company, while TuHURA shareholders will maintain about 97.15%. The merger is subject to customary closing conditions and is expected to be finalized by the third quarter of 2024.
Read more →HURAWe ask that ALL Kintara stockholders VOTE their shares TODAY! Voting deadline is September 19 th at 11:59 p.m., EST Your vote “FOR” each proposal will allow for the completion of the proposed merger with Tu
Kintara is urging its stockholders to vote for proposals related to its merger with TuHURA, with the voting deadline set for September 19, 2024. Successful approval is crucial as it will enable the merger to proceed, leading to a focus on immunotherapies for cancer. Without sufficient votes, Kintara risks bankruptcy and possible delisting from the Nasdaq. If approved, stockholders will receive contingent rights linked to the success of the REM-001 program.
Read more →HURATuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer 30 of a projected 39 patients have been en
TuHURA Biosciences and Kintara Therapeutics have announced the reopening of enrollment for the VISTA-101 clinical trial, which evaluates the immunotherapy KVA12123 in patients with advanced solid tumors. Currently, 30 out of a projected 39 patients have been enrolled, with plans to complete enrollment by the end of 2024. Initial results from the trial indicate promising safety and tolerability profiles, alongside evidence of partial responses in treated patients. This collaboration is part of a broader agreement where TuHURA seeks to acquire rights related to KVA12123, which may enhance its clinical pipeline.
Read more →HURATuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor KVA12123 is a rationally targeted, anti-VISTA antibody checkpoint inhibitor
TuHURA Biosciences has signed an Exclusivity and Right of First Offer Agreement with Kineta, Inc. for KVA12123, a novel anti-VISTA checkpoint inhibitor. KVA12123 is designed to counter VISTA-mediated immune suppression and improve the tumor microenvironment. Currently undergoing clinical trials as a monotherapy and in combination with KEYTRUDA, KVA12123 has exhibited a favorable safety profile, making it a compelling addition to TuHURA's pipeline. The agreement involves a $5 million payment structure, part of which will bolster TuHURA's ongoing Phase 3 trials.
Read more →HURAKintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones
Kintara Therapeutics and TuHURA Biosciences have announced significant progress with their recent merger and clinical advancements. The merger is expected to be finalized in the third quarter of 2024, allowing both companies to bolster their cancer treatment capabilities. Furthermore, TuHURA is preparing for a Phase 3 trial of its personalized cancer vaccine targeting advanced Merkel cell carcinoma with expected regulatory support. The ongoing clinical studies, particularly for Kintara's REM-001 therapy, are expanding patient enrollment to enhance treatment outcomes.
Read more →HURATuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutane
TuHURA Biosciences and Kintara Therapeutics reported favorable results from their Phase 1b trial of IFx-2.0, a personalized cancer vaccine targeting checkpoint inhibitor-resistant advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC). The trial showed that 80% of ICI naive patients who had previously failed other treatments saw significant responses following IFx-2.0 therapy. The study established the safety profile of IFx-2.0 and led to plans for a Phase 3 trial, which will investigate its effectiveness as an adjunct therapy with Keytruda. This development comes as part of the companies' broader strategy to enhance cancer treatment options.
Read more →HURAKintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results
Kintara Therapeutics reported its fiscal third quarter financial results for 2024, highlighting a merger agreement with TuHURA Biosciences to enhance its cancer therapy pipeline. The financial report indicated a reduced net loss compared to the previous year, primarily due to lower clinical development costs. Kintara is expanding its REM-001 study to include patients who have undergone prior treatments, with enhancements aimed at optimizing outcomes before a Phase 3 trial. The merger is set to further develop Kintara's novel therapies aimed at unmet medical needs in oncology.
Read more →HURATuHURA Biosciences to Present Its IFx-2.0 Personalized Cancer Vaccine Clinical Trial Results at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting TAMPA, FL &
TuHURA Biosciences announces that its IFx-2.0 Phase 1b clinical trial results will be presented at the 2024 ASCO Annual Meeting. The session will focus on their innovative personalized cancer vaccine aimed at overcoming resistance to immunotherapy in specific cancer types. Additionally, TuHURA has finalized an agreement to merge with Kintara Therapeutics, which will combine resources to advance their oncology pipeline, including personalized vaccines and bi-specific antibody drug conjugates.
Read more →HURAKintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement • TuHURA is planning to advance a single Phase 3 trial for IFx-2.0 personalized cancer vaccine as adjunctive therapy with Keytruda
Kintara Therapeutics and TuHURA Biosciences have entered into a definitive merger agreement, aiming to create a single entity focused on enhancing cancer therapies. TuHURA plans to initiate a Phase 3 trial for its IFx-2.0 personalized cancer vaccine in conjunction with Keytruda for advanced Merkel cell carcinoma. The merger is complemented by a $31 million financing round, which is intended to fund operations through late 2025. Expected to be finalized in Q3 2024, the merger will position the combined company to develop novel immunotherapies while overcoming existing treatment limitations.
Read more →HURAKintara Therapeutics Announces Fiscal 2024 Second Quarter Financial Results and Provides Corporate Update
Kintara Therapeutics announced its fiscal 2024 Q2 financial results and a corporate update, focusing on the initiation of a new clinical study for REM-001 therapy targeting cutaneous metastatic breast cancer. The company reported a reduced net loss from the previous year, mainly due to lower research and administrative expenses. Despite the termination of its VAL-083 program, Kintara remains focused on maximizing shareholder value and has engaged a financial advisor to explore strategic alternatives.
Read more →HURAKintara Therapeutics Announces Initiation of REM-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast Cancer - 15-patient Open Label Study to Confirm Planned Dose and Optimized Study Design Leading to a Ph
Kintara Therapeutics has initiated a 15-patient open label clinical trial for REM-001, a photodynamic therapy aimed at treating cutaneous metastatic breast cancer (CMBC). The trial's primary goal is to confirm the planned dosage and optimize the study design for a subsequent Phase 3 trial. Supported by a $2 million grant from the NIH, the company aims to address a critical medical need, given CMBC's devastating impact and limited treatment options. Previously, REM-001 has shown an 80% complete response rate in late-stage trials, underscoring its potential efficacy in this patient population.
Read more →HURAKintara Therapeutics Announces Review of Strategic Alternatives - Ladenburg Thalmann Hired as Financial advisor
Kintara Therapeutics has announced that its Board of Directors will explore a range of strategic alternatives aimed at maximizing stockholder value. The company has retained Ladenburg Thalmann & Co. as its financial advisor for this review process. While Kintara provides innovative therapies for cancer, including the promising REM-001 treatment for cutaneous metastatic breast cancer, there is no guarantee that this strategic review will lead to any specific actions or transactions. Future communications regarding this process will only occur if a specific strategy is approved.
Read more →HURAKintara Therapeutics Granted Extension by Nasdaq to Regain Compliance with the Stockholders' Equity Continued Listing Requirement
Kintara Therapeutics has secured an extension from Nasdaq to comply with stockholders' equity requirements, providing until March 18, 2024, to meet criteria. This extension follows the submission of a compliance plan by the Company. The deadline is contingent upon achieving specified milestones. Failure to comply could result in delisting, although the Company may appeal such a decision, which would allow it to remain listed during the appeal process. Kintara continues its focus on developing innovative cancer therapies aimed at unmet medical needs.
Read more →HURAKintara Therapeutics Announces Fiscal 2024 First Quarter Financial Results and Provides Corporate Update
Kintara Therapeutics announced its fiscal 2024 first quarter financial results, revealing a net loss of approximately $3 million, a decrease from $4.6 million the previous year. The company has suspended the development of its glioblastoma therapy, VAL-083, after disappointing trial results but is redirecting focus to their REM-001 program for cutaneous metastatic breast cancer. Kintara has secured a $2 million NIH grant to support this initiative. However, the overall financial health remains concerning with a significant drop in cash reserves and a working capital deficiency.
Read more →HURAKintara Therapeutics Announces Preliminary Topline Results From GBM AGILE Study - VAL-083 Did Not Perform Better Than Current Standards of Care - - Company Suspending Development of VAL-083, Shifting Focus to REM-001 Pro
Kintara Therapeutics has announced preliminary topline results from the GBM AGILE study indicating that its treatment VAL-083 did not outperform current standards of care for glioblastoma. Consequently, the company is suspending its development and shifting focus to its REM-001 program for cutaneous metastatic breast cancer (CMBC). Additionally, Kintara has been awarded a $2 million grant from the NIH to aid in the CMBC study, which is expected to begin shortly. The firm remains committed to exploring strategic opportunities to enhance shareholder value while awaiting final results from the ongoing studies.
Read more →HURAKintara Therapeutics Announces Fiscal 2023 Year Financial Results and Provides Corporate Update
Kintara Therapeutics reported its financial results for the fiscal year ended June 30, 2023, revealing a net loss of approximately $14.6 million, a significant improvement from the previous year's loss. The company received a $2 million grant from the NIH for the development of REM-001, a treatment for cutaneous metastatic breast cancer. Kintara plans to present learnings on its VAL-083 program at an upcoming conference and anticipates enrollment in a clinical study for REM-001 soon. However, the company faces concerns regarding its cash reserves and overall financial stability.
Read more →HURAKintara Therapeutics Announces Fiscal 2023 Third Quarter Financial Results and Provides Corporate Update
Kintara Therapeutics announced its financial results for the fiscal third quarter ended March 31, 2023, revealing a reduced net loss compared to the same period last year. Recent case studies from the American Association for Cancer Research highlighted the potential of VAL-083 in treating specific recurrent brain tumors. Despite the positive developments for VAL-083, Kintara has paused its REM-001 therapy program to manage cash flow concerns, with approximately $3 million in cash reserves reported.
Read more →HURAKintara Therapeutics Announces Fiscal 2023 Second Quarter Financial Results and Provides Corporate Update
Kintara Therapeutics reported its fiscal 2023 second quarter financial results, showing a net loss of $3.5 million. The company received Orphan Drug Designation for its drug VAL-083, which targets a rare brain cancer, and regained compliance with Nasdaq regulations. However, it paused its REM-001 therapy program to manage cash resources, despite progress towards the upcoming GBM AGILE Study results. Kintara aims to advance its VAL-083 program while maintaining fiscal prudence amidst its ongoing operations.
Read more →HURAKintara Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Kintara Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement SAN DIEGO, November 30, 2022 -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ( Kintara or the Company ), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, tod
Read more →HURAKintara Therapeutics Announces Fiscal 2023 First Quarter Financial Results and Provides Corporate Update
Kintara Therapeutics Announces Fiscal 2023 First Quarter Financial Results and Provides Corporate Update SAN DIEGO, November 9, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ( Kintara or the Company ), a biopharmaceutical company focused on the development of ne
Read more →HURAKintara Therapeutics Pauses REM-001 Program to Conserve Funds to Support VAL-083 International Registrational Study REM-001 15-Patient Study Paused to Conserve Funds – Approximately $3 Million Saved through 2023
Kintara Therapeutics Pauses REM-001 Program to Conserve Funds to Support VAL-083 International Registrational Study REM-001 15-Patient Study Paused to Conserve Funds Approximately $3 Million Saved through 2023 SAN DIEGO, October 19, 2022 /PRNewswire/ -- Kintara Therapeutics, In
Read more →HURAKintara Therapeutics Announces Fiscal 2022 Financial Results and Provides Corporate Update
Kintara Therapeutics Announces Fiscal 2022 Financial Results and Provides Corporate Update SAN DIEGO, Sept. 27, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ( Kintara or the Company ), a biopharmaceutical company focused on the development of new solid tumor ca
Read more →HURAKintara Therapeutics Enters Into Equity Purchase Agreement for Up to $20 Million with Lincoln Park Capital
Kintara Therapeutics Enters Into Equity Purchase Agreement for Up to $20 Million with Lincoln Park Capital SAN DIEGO, August 3, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) (Kintara or the Company), a biopharmaceutical company focused on the development of new
Read more →HURAKintara Therapeutics Granted Fast Track Designation from the FDA for VAL-083 for Newly-Diagnosed Glioblastoma
Kintara Therapeutics Granted Fast Track Designation from the FDA for VAL-083 for Newly-Diagnosed Glioblastoma SAN DIEGO, June 15, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ( Kintara or the Company ), a biopharmaceutical company focused on the development of
Read more →HURAKintara Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement
Kintara Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement SAN DIEGO, June 3, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ( Kintara or the Company ), a biopharmaceutical company focused on the development of new solid tumor cancer therapies
Read more →HURAKintara Therapeutics Announces Fiscal 2022 Third Quarter Financial Results and Provides Corporate Update
Kintara Therapeutics Announces Fiscal 2022 Third Quarter Financial Results and Provides Corporate Update SAN DIEGO, May 13, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ( Kintara or the Company ), a biopharmaceutical company focused on the development of new so
Read more →HURAKintara Announces $8.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Kintara Announces $8.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules SAN DIEGO, April 12, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ( Kintara or the Company ), a biopharmaceutical company focused on the development of new solid t
Read more →HURAKintara Therapeutics Announces Fiscal 2022 Second Quarter Financial Results and Provides Corporate Update SAN DIEGO, February 11, 2 022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company
Kintara Therapeutics Announces Fiscal 2022 Second Quarter Financial Results and Provides Corporate Update SAN DIEGO, February 11, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development o
Read more →HURAForward Looking Statements 2 This presentation contains forward-looking statements based upon Kintara's current expectations. This communication contains "forward-looking statements" within the meaning of the Private Sec
Developing Advanced Oncology Therapies for Rare Unmet Medical Needs Copyright 2022 Kintara Therapeutics, Inc. CONFIDENTIAL Corporate Presentation January 2022 Exhibit 99.1 Forward Looking Statements 2 This presentation contains forward-looking statements based upon Kintara's cur
Read more →HURAKintara Therapeutics Announces Fiscal 2022 First Quarter Financial Results and Provides Corporate Update SAN DIEGO, November 15, 2 021 /PRNewswire/ -- https://www.kintara.com/ (Nasdaq: KTRA) ("Kintara" or the "Company"),
Kintara Therapeutics Announces Fiscal 2022 First Quarter Financial Results and Provides Corporate Update SAN DIEGO, November 15, 2021 /PRNewswire/ -- https://www.kintara.com/ (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of n
Read more →HURAKintara Therapeutics Announces Fiscal Year 2021 Financial Results and Provides Corporate Update SAN DIEGO, September 29, 2 021 /PRNewswire/ -- https://www.kintara.com/ (Nasdaq: KTRA) ("Kintara" or the "Company"), a bioph
Kintara Therapeutics Announces Fiscal Year 2021 Financial Results and Provides Corporate Update SAN DIEGO, September 29, 2021 /PRNewswire/ -- https://www.kintara.com/ (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid
Read more →HURAKintara Announces $15.0 million Offering of Common Stock and Warrants Priced at a Premium to Market
Kintara Announces $15.0 million Offering of Common Stock and Warrants Priced at a Premium to Market SAN DIEGO, Sept. 24, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company developing novel cancer therapies for
Read more →HURAKintara Therapeutics Announces Fiscal Third Quarter 2021 Financial Results and Provides Corporate Update SAN DIEGO, May 14, 2 021 /PRNewswire/ -- https://www.kintara.com/ (Nasdaq: KTRA) ("Kintara" or the "Company"), a bi
Kintara Therapeutics Announces Fiscal Third Quarter 2021 Financial Results and Provides Corporate Update SAN DIEGO, May 14, 2021 /PRNewswire/ -- https://www.kintara.com/ (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new so
Read more →HURAKintara Therapeutics Announces Fiscal Second Quarter 2021 Financial Results and Provides Corporate Update
Kintara Therapeutics Announces Fiscal Second Quarter 2021 Financial Results and Provides Corporate Update SAN DIEGO, February 12, 2021 /PRNewswire/ Kintara Therapeutics, Inc. (Nasdaq: KTRA) ( Kintara or the Company ), a biopharmaceutical company focused on the development of ne
Read more →HURAKintara Therapeutics Announces First Fiscal Quarter 2021 Financial Results and Recent Corporate Updates
Kintara Therapeutics Announces First Fiscal Quarter 2021 Financial Results and Recent Corporate Updates SAN DIEGO, November 13, 2020 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of
Read more →HURAKintara Therapeutics Announces Fiscal Year 2020 Financial Results and Recent Corporate Updates
Kintara Therapeutics Announces Fiscal Year 2020 Financial Results and Recent Corporate Updates SAN DIEGO, September 21, 2020 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new soli
Read more →HURAKintara Therapeutics Completes Final Closing of Previously Announced Private Placement For an Aggregate of $25 Million - Launches Strategic Growth Initiative of Expanded Late-stage Oncology Pipeline
Therapeutics Completes Final Closing of Previously Announced Private Placement For an Aggregate of $25 Million - Launches Strategic Growth Initiative of Expanded Late-stage Oncology Pipeline - SAN DIEGO, Sept 1, 2020 /PRNewswire/ -- Kintara Therapeutics, Inc. ("Kintara" or th
Read more →HURAKintara Therapeutics Announces Additional $2.4 Million Private Placement Priced At-The-Market
Kintara Therapeutics Announces Additional $2.4 Million Private Placement Priced At-The-Market SAN DIEGO, Aug. 21, 2020 - Kintara Therapeutics, Inc. (formerly DelMar Pharmaceuticals, Inc.) ("Kintara" or the "Company") (Nasdaq: KTRA) announced today that it has entered into def
Read more →HURADelMar Announces $19.6 Million Private Placement Priced At-The-Market
DelMar Announces $19.6 Million Private Placement Priced At-The-Market SAN DIEGO, August 18, 2020 - DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company") announced today that it has entered into definitive agreements with investors providing for the sale and
Read more →HURADelMar Announces Approval of Merger by Stockholders
DelMar Announces Approval of Merger by SAN DIEGO, August 17, 2020 - DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company") announced today that all proposals related to the proposed merger between DelMar and Adgero were approved by DelMar's stockholders at a s
Read more →HURAForward Looking Statements and Confidentiality Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securiti
Corporate Presentation of Company following acquisition of Adgero ("Kintara Therapeutics") June 2020 Copyright 2020 DelMar Pharmaceuticals Inc. Exhibit 99.1 Forward Looking Statements and Confidentiality Any statements contained in this presentation that do not describe histor
Read more →HURADelMar to Acquire Adgero Biopharmaceuticals, Expands Late-Stage Oncology Pipeline Combination creates a diversified biopharmaceutical company with a robust product pipeline targeting rare, unmet medical needs in oncology
DelMar to Acquire Adgero Biopharmaceuticals, Expands Late-Stage Oncology Pipeline Combination creates a diversified biopharmaceutical company with a robust product pipeline targeting rare, unmet medical needs in oncology Pipeline led by two late-stage, Phase 3-ready cancer ther
Read more →HURADelMar Pharmaceuticals Announces Fiscal Third Quarter 2020 Financial Results and Recent Corporate Updates
DelMar Pharmaceuticals Announces Fiscal Third Quarter 2020 Financial Results and Recent Corporate Updates SAN DIEGO, California, May 13, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the de
Read more →HURADelMar Pharmaceuticals Receives Nasdaq Bid Price Extension
DelMar Pharmaceuticals Receives Nasdaq Bid Price Extension SAN DIEGO, March 26, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced
Read more →HURAPharmaceuticals Announces Fiscal Second Quarter 2020 Financial Results and Recent Corporate Updates
Pharmaceuticals Announces Fiscal Second Quarter 2020 Financial Results and Recent Corporate Updates SAN DIEGO, California, February 13, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the deve
Read more →HURADelMar Pharmaceuticals, Inc. Edited Transcript of Key Opinion Leader Event
DelMar Pharmaceuticals, Inc. Edited Transcript of Key Opinion Leader November 22, 2019 at the Annual Meeting of the Society for Neuro-Oncology Saiid Zarrabian, President and CEO of DelMar Pharmaceuticals Dennis Brown, Chief Scientific Officer of DelMar Pharmaceuticals Greg
Read more →HURACurrent standard - of - care for glioblastoma (GBM) includes surgery followed by concurrent therapy with radiation and temozolomide (TMZ) followed by adjuvant TMZ (days 1 - 5 eve
| Current standard - of - care for glioblastoma (GBM) includes surgery followed by concurrent therapy with radiation and temozolomide (TMZ) followed by adjuvant TMZ (days 1 - 5 every 28 days) . Almost all GBM patients experience recurrent/progressive disease, with a median surviv
Read more →HURAPharmaceuticals Announces Fiscal Year 2019
Pharmaceuticals Announces Fiscal Year 2019 Financial Results and Recent Corporate Updates Company Estimates Cash Runway Sufficient to Report Top-Line Results from Two of Three Patient Groups in Phase 2 Trials By 4th Quarter of Calendar Year 2020 SAN DIEGO, California, Septemb
Read more →HURADelMar Pharmaceuticals Reports Full
DelMar Pharmaceuticals Reports Full Compliance with Nasdaq Listing Criteria SAN DIEGO, California, September 9, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of novel cancer
Read more →HURABreakthrough Cancer Therapeutics VAL - 083: Validated DNA - targeting Agent for Multiple Drug Resistant Solid Tumor Indications August 2019 NASDAQ: DMPI Forward Looking Statements Copyright 2019, DelMar Pharmaceuticals A
Cancer Therapeutics VAL - 083: Validated DNA - targeting Agent for Multiple Drug Resistant Solid Tumor Indications August 2019 that do not describe historical facts may constitute forward - looking statements as that term is defined in the Private Securities Litigation Reform A
Read more →HURADELMAR PHARMACEUTICALS ANNOUNCES PRICING
DELMAR PHARMACEUTICALS ANNOUNCES PRICING OF $6.8 MILLION UNDERWRITTEN PUBLIC OFFERING VANCOUVER, British Columbia and MENLO PARK, Calif., August 14, 2019 -- DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the dev
Read more →HURAFINANCIAL STATEMENTS OF DELMAR PHARMACEUTICALS, INC DelMar Pharmaceuticals, Inc. INDEX TO FINANCIAL STATEMENTS Contents Page Consolidated Financial Statements
DelMar Pharmaceuticals, Inc. INDEX TO FINANCIAL STATEMENTS Page Consolidated Financial Statements - June 30, 2018 and 2017: Report of Independent Registered Public Accounting Firm F-2 Consolidated Balance Sheets as of June 30, 2018 and 2017 F-3 Consolidated Statements of
Read more →HURADELMAR PHARMACEUTICALS ANNOUNCES $3.6
DELMAR PHARMACEUTICALS ANNOUNCES $3.6 MILLION REGISTERED DIRECT VANCOUVER, British Columbia and MENLO PARK, Calif., June 3, 2019 -- DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development and commercializ
Read more →HURADelMar Pharmaceuticals Announces Third
DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2019 Financial Results - Company will host a business update May 23, 2019 at 4:30 PM Eastern Time VANCOUVER, British Columbia and MENLO PARK, California, May 15, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nas
Read more →HURADelMar Pharmaceuticals Announces 1-for-10 Reverse Stock Split VANCOUVER, British Columbia and
DelMar Pharmaceuticals Announces 1-for-10 Reverse Stock Split VANCOUVER, British Columbia and MENLO PARK, California., May 7, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development a
Read more →HURAPharmaceuticals Announces Second Quarter
Pharmaceuticals Announces Second Quarter Fiscal Year 2019 Financial Results Company will host a business update conference call on February 19, 2019 at 4:30 PM Eastern Time - VANCOUVER, British Columbia and MENLO PARK, California, February 12, 2019 /PRNewswire/ -- DelMar Phar
Read more →HURAPharmaceuticals Announces First Quarter Fiscal Year 2019 Financial Results
Pharmaceuticals Announces First Quarter Fiscal Year 2019 Financial Results Company will host a business update conference call on 20, 2018 at 4:30 PM Eastern Time - British Columbia and MENLO PARK, California, November 14, 2018 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NAS
Read more →HURADelMar Pharmaceuticals Announces Fiscal Year 2018 Annual Financial Results - Company will host a business update conference call on
Pharmaceuticals Announces Fiscal Year 2018 Annual Financial Results Company will host a business update conference call on September 25, 2018 at 4:30 PM Eastern Time - British Columbia and MENLO PARK, California, September 24, 2018 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (
Read more →HURAAppoints Saiid Zarrabian to Full-Time President and CEO
Appoints Saiid Zarrabian to Full-Time President and CEO British Columbia and MENLO PARK, Calif., May 22, 2018 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (the "Company")(NASDAQ: DMPI) today announced that the board of directors (the "Board") has appointed Saiid Zarrabian as th
Read more →HURADelMar Pharmaceuticals Announces
DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2018 Financial Results - Company will host a business update conference call on May 30, 2018 at 4:30 PM Eastern Time - VANCOUVER, British Columbia and MENLO PARK, Calif., May, 17, 2018 /PRNewswire/ -- DelMar Pharmace
Read more →HURADelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2018 Financial Results - Company will host a business update conference call on Tuesday
DelMar Pharmaceuticals Announces Second Fiscal Year 2018 Financial Results - Company will host a business update conference call on Tuesday, February 20, 2018 at 4:30 PM EST - VANCOUVER, British Columbia and MENLO PARK, Calif., February 14, 2018 /PRNewswire/ - DelMar Pharmac
Read more →HURADelMar Presents Positive Interim Results from VAL-083 Study in MGMT-unmethylated Recurrent GBM at The Society for NeuroOncology Annual Meeting 40% of recurrent GBM patients treated to date achieved stable disease as meas
Presents Positive Interim Results from VAL-083 Study in MGMT-unmethylated Recurrent GBM at The Society for NeuroOncology Annual Meeting of recurrent GBM patients treated to date achieved stable disease as measured by magnetic resonance imaging (MRI) British Columbia and MENLO
Read more →HURADelMar Pharmaceuticals Appoints Saiid Zarrabian as Interim Chief Executive Officer VANCOUVER, British Columbia and
Pharmaceuticals Appoints Saiid Zarrabian as Interim Chief Executive Officer British Columbia and MENLO PARK, Calif., November 7, 2017 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" and "the Company"), a biopharmaceutical company focused on the development
Read more →HURACopyright 2017, DelMar Pharmaceuticals All rights reserved Seeking New Horizons for Cancer Patients Corporate Update NASDAQ: DMPI
Any forward - looking statements contained herein or made in the course of the presentation are based on current expectations, but are subject to a number of risks and uncertainties . The factors that could cause actual future results to differ materially from current expectation
Read more →HURAPHARMACEUTICALS ANNOUNCES $10 MILLION REGISTERED DIRECT
PHARMACEUTICALS ANNOUNCES $10 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET British Columbia and MENLO PARK, Calif., September 20, 2017 / -- DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the developmen
Read more →HURAPHARMACEUTICALS ANNOUNCES PRICING OF $9,000,000 MILLION PUBLIC
PHARMACEUTICALS ANNOUNCES PRICING OF $9,000,000 MILLION PUBLIC OFFERING OF COMMON STOCK AND WARRANTS Columbia and MENLO PARK, Calif., April 13, 2017 / -- DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the develop
Read more →HURADelMar Pharmaceuticals Announces First Quarter Fiscal Year 2017 Financial Results and Corporate Update - Company will host a business update conference call and webcast on Tuesday
Pharmaceuticals Announces First Quarter Fiscal Year 2017 Financial Results and Corporate Update Company will host a business update conference call and webcast on Tuesday, November 15, 2016 at 4:30 PM EST - Company also highlights recent corporate and clinical achievements and
Read more →HURADelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2016 Financial Results and Corporate Update - Business update conference call and webcast on
DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2016 Financial Results and Corporate Update - Business update conference call and webcast on May 19, 2016 at 5 PM EST - British Columbia and MENLO PARK, Calif., May 13, 2016 /PRNewswire/ -- DelMar Pharmaceuticals, Inc
Read more →HURADelMar Pharmaceuticals Reports First Quarter Fiscal Year 2016 Financial Results and Provides Corporate Update - Management to host business update conference call and webcast on Monday
Pharmaceuticals Reports First Quarter Fiscal Year 2016 Financial Results and Provides Corporate Update to host business update conference call and webcast on Monday, November 23, 2015 at 4:30 p.m. ET / 1:30 p.m. PT - British Columbia and MENLO PARK, Calif., November 17, 2015 /P
Read more →HURADelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2015 Financial Results and Provides Corporate Update - Lead product candidate, VAL-083 for the treatment of glioblastoma multiforme (GBM), positioned to enter re
Pharmaceuticals Announces Third Quarter Fiscal Year 2015 Financial Results and Provides Corporate Update Lead product candidate, VAL-083 for the treatment of glioblastoma multiforme (GBM), positioned to enter registration-directed Phase II/III clinical trials in 2H 2015 - Brit
Read more →HURADelMar Pharmaceuticals Completes Offer to Exchange Common Stock for Outstanding Warrants VANCOUVER, British Columbia and
DelMar Pharmaceuticals Completes Offer to Exchange Common Stock for Outstanding Warrants British Columbia and MENLO PARK, Calif., February 10, 2015 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), today announced that it has completed a
Read more →HURADelMar Pharmaceuticals Commences Offer to Exchange Common Stock for Outstanding Warrants VANCOUVER, British Columbia, and MENLO PARK, Calif./PR Newswire/
Pharmaceuticals Commences Offer to Exchange Common Stock for Outstanding Warrants British Columbia, and MENLO PARK, Calif./PR Newswire/ January 8, 2015 -- DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company", "we" or "our") today announced that it has commence
Read more →HURADelMar Pharmaceuticals, Inc.
To record proceeds of $738,626 from the exercise of 1,136,347 warrants at $0.65 per warrant and to record the reclassification of the pro rata portion of the related derivative liability to equity. 2. To record the reclassification of the Dividend Warrant portion of the derivativ
Read more →HURAELECTION TO EXERCISE WARRANTS To: ____, 2014 DelMar Pharmaceuticals, Inc. Suite 720 - 999 West Broadway Vancouver, British Columbia CANADA V5Z 1K5 Attn: Corporate Secretary Fax. No. 604.608.5685 Reference is made to the
ELECTION TO EXERCISE WARRANTS To: ____, 2014 DelMar Pharmaceuticals, Inc. Suite 720 - 999 West Broadway Vancouver, British Columbia CANADA V5Z 1K5 Attn: Corporate Secretary Fax. No. 604.608.5685 Reference is made to the Warrant to purchase __________________shares of the Com
Read more →HURABERRY ONLY INC. PRO FORMA CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) (Expressed in United States Dollars, except where specified otherwise) SEPTEMBER 30, 2012 1 BERRY ONLY INC. PRO FORMA CONSOLIDATED BALANCE SHEET AS
PRO FORMA CONSOLIDATED FINANCIAL STATEMENTS (Expressed in United States Dollars, except where specified otherwise) PRO FORMA CONSOLIDATED BALANCE SHEET AS AT SEPTEMBER 30, 2012 (Expressed in United States Dollars, except where specified otherwise) Assets DelMar Pharmaceutic
Read more →Competitive Position
How HURA ranks across every disease it competes inCompetitive Position is a premium feature
See how HURA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial